Changes in Beneficial Ownership · 4
Annexon, Inc.
ANNXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06152026_040603.xml
Filing details
- Report period
- 2026-06-11
- Issuer
- Annexon, Inc.
- Issuer CIK
- 0001528115
- Trading symbol
- ANNX
Reporting owner 1
- Name
- Carson William H.
- Reporting owner CIK
- 0001824280
- Relationship
- Director
- Address
- C/O ANNEXON, INC., 1400 SIERRA POINT PKWY, BLDG C, STE 200, BRISBANE, CA, 94005
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 4.70 | 2026-06-11 | A · Form 4 | 65,000 | A | 0 | [F1] | 2036-06-11 | Common Stock | 65,000 | 65,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.↩ 1
Signature 1
- Signed
- /s/ Jennifer Lew, Attorney-in-Fact
- Date
- 2026-06-15
Company context
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Current securities
Recent company filings
- 10-Q filingAug 12, 2026
- Results of Operations and Financial Condition · Other EventsAug 12, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureAug 10, 2026
- Other EventsAug 6, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Other EventsJul 30, 2026